Karyomapping is a new single gene PGD test available in-house. Karyomapping is suitable for patients with a family history of a single gene disorder who are at risk of producing embryos that are affected by that single gene disorder including Cystic Fibrosis, Fragile X, Beta-thalassaemia, or Spinal Muscular Atrophy.
What are the benefits of Karyomapping?
Karyomapping offers several significant benefits including:
- A significant reduction in the timeframe required to perform the test. As the testing is performed on a standardised platform, there is no need to tailor design a specific test for each couple. As a result, the turnaround time for testing is only 2-4 weeks.
- Karyomapping has the potential to detect some chromosome abnormalities which may be associated with implantation failure, miscarriage, or abnormalities at birth. While the testing is not specifically designed to screen for chromosome abnormalities and there is no guarantee that all chromosome abnormalities will be detected, this does represent a significant improvement compared to the previous test.
- Karyomapping is more cost effective. This testing is charged at $700 per biopsied embryo, with the fee capped at $2460 per PGD cycle.
To learn more about Karyomapping please call us on (08) 8333 8111 or complete the enquiry form below.
Learn more about our suite of Embryo Genetic Testing here
[contact-form-7 id=”463″ title=”Enquiry”]